Popular GLP-1 medications like semaglutide and tirzepatide have been linked to rare vision issues, including NAION, raising ...

Add surgical tweaks to fix so-called "Ozempic face" to the list of top trending cosmetic procedures, as tallied by the ...

Pharma giant Novo Nordisk, the company behind Wegovy and Ozempic, expects to launch six products in the next five years. Leading the pack of new drugs will be CagriSema.

A new poll from The Associated Press-NORC Center for Public Affairs Research shows about half of U.S. adults believe it is a good thing for adults to use weight-loss drugs like Ozempic, Wegovy and ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

achieved weight loss of 22% on a 20 milligram once-per-week dose taken for 36 weeks. Steven Goldstein is based in London and responsible for MarketWatch's coverage of financial markets in Europe ...

The new drug, amycretin, similar to the company's blockbuster weight ... Ozempic, provided weight loss of up to 22% in early-stage clinical trials. The company tested the once-weekly injection on 125 ...

Popular GLP-1 agonists include Novo Nordisk’s own Wegovy and Ozempic ... weight loss than popular weekly injection Wegovy. Novo Nordisk said that patients that took a once-daily 50mg dose ...

Amycretin trial showed weight loss ... and dose-response trial investigating three different maintenance doses with a total treatment duration of up to 36 weeks. Also Read: Popular Ozempic ...